Literature DB >> 24458438

The cytokine midkine supports neutrophil trafficking during acute inflammation by promoting adhesion via β2 integrins (CD11/CD18).

Ludwig T Weckbach1, Anita Gola, Michael Winkelmann, Sascha M Jakob, Leopold Groesser, Julia Borgolte, Frank Pogoda, Robert Pick, Monika Pruenster, Josef Müller-Höcker, Elisabeth Deindl, Markus Sperandio, Barbara Walzog.   

Abstract

Emerging evidence suggests a role of the cytokine midkine (MK) in inflammation. In this study, its functional relevance for recruitment of polymorphonuclear neutrophils (PMNs) during acute inflammation was investigated. Intravital microscopy and histologic analysis of tumor necrosis factor-α-stimulated cremaster muscle venules revealed severely compromised leukocyte adhesion and extravasation in MK(-/-) mice compared with MK(+/+) animals. Systemic administration of recombinant MK completely rescued the adhesion defect in MK(-/-) mice. In a hind limb ischemia model, leukocyte accumulation in MK(-/-) mice was significantly diminished compared with MK(+/+) animals. However, MK did not lead to an inflammatory activation of PMNs or endothelial cells suggesting that it does not serve as classical proinflammatory cytokine. Unexpectedly, immobilized MK mediated PMN adhesion under static and flow conditions, whereas PMN-derived MK was dispensable for the induction of adhesion. Furthermore, adhesion strengthening remained unaffected by MK. Flow cytometry revealed that immobilized, but not soluble MK, significantly promoted the high affinity conformation of β2 integrins of PMNs. Blocking studies of low-density lipoprotein receptor-related protein 1 (LRP1) suggested that LRP1 may act as a receptor for MK on PMNs. Thus, MK seems to support PMN adhesion by promoting the high affinity conformation of β2 integrins, thereby facilitating PMN trafficking during acute inflammation.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24458438     DOI: 10.1182/blood-2013-06-510875

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  32 in total

1.  Midkine, a middle manager of β2 integrins.

Authors:  Jan M Herter; Tanya N Mayadas
Journal:  Blood       Date:  2014-03-20       Impact factor: 22.113

Review 2.  Emerging risk biomarkers in cardiovascular diseases and disorders.

Authors:  Ravi Kant Upadhyay
Journal:  J Lipids       Date:  2015-04-08

3.  Low-density lipoprotein receptor-related protein 1 attenuates house dust mite-induced eosinophilic airway inflammation by suppressing dendritic cell-mediated adaptive immune responses.

Authors:  Amarjit Mishra; Xianglan Yao; Ankit Saxena; Elizabeth M Gordon; Maryann Kaler; Rosemarie A Cuento; Amisha V Barochia; Pradeep K Dagur; J Philip McCoy; Karen J Keeran; Kenneth R Jeffries; Xuan Qu; Zu-Xi Yu; Stewart J Levine
Journal:  J Allergy Clin Immunol       Date:  2017-12-21       Impact factor: 10.793

Review 4.  Pleiotrophin: Activity and mechanism.

Authors:  Xu Wang
Journal:  Adv Clin Chem       Date:  2020-03-12       Impact factor: 5.394

5.  Pleiotrophin, a multifunctional cytokine and growth factor, induces leukocyte responses through the integrin Mac-1.

Authors:  Di Shen; Nataly P Podolnikova; Valentin P Yakubenko; Christopher L Ardell; Arnat Balabiyev; Tatiana P Ugarova; Xu Wang
Journal:  J Biol Chem       Date:  2017-09-22       Impact factor: 5.157

Review 6.  From top to bottom: midkine and pleiotrophin as emerging players in immune regulation.

Authors:  Noah Sorrelle; Adrian T A Dominguez; Rolf A Brekken
Journal:  J Leukoc Biol       Date:  2017-03-29       Impact factor: 4.962

7.  Low density lipoprotein receptor-related protein 1 couples β1 integrin activation to degradation.

Authors:  Lukasz Wujak; Ralph T Böttcher; Oleg Pak; Helena Frey; Elie El Agha; Ying Chen; Sigrid Schmitt; Saverio Bellusci; Liliana Schaefer; Norbert Weissmann; Reinhard Fässler; Malgorzata Wygrecka
Journal:  Cell Mol Life Sci       Date:  2017-11-07       Impact factor: 9.261

Review 8.  Regulation of tissue infiltration by neutrophils: role of integrin α3β1 and other factors.

Authors:  Pallavi Subramanian; Ioannis Mitroulis; George Hajishengallis; Triantafyllos Chavakis
Journal:  Curr Opin Hematol       Date:  2016-01       Impact factor: 3.284

Review 9.  Midkine (MDK) growth factor: a key player in cancer progression and a promising therapeutic target.

Authors:  Panagiota S Filippou; George S Karagiannis; Anastasia Constantinidou
Journal:  Oncogene       Date:  2019-12-04       Impact factor: 9.867

10.  Protease nexin-1 deficiency increases mouse hindlimb neovascularisation following ischemia and accelerates femoral artery perfusion.

Authors:  Sonia Selbonne; Celina Madjene; Benjamin Salmon; Yacine Boulaftali; Marie-Christine Bouton; Véronique Arocas
Journal:  Sci Rep       Date:  2021-06-28       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.